Nwam LLC Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Nwam LLC lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 906 shares of the biopharmaceutical company’s stock after buying an additional 50 shares during the quarter. Nwam LLC’s holdings in Alnylam Pharmaceuticals were worth $213,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after purchasing an additional 66,928 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 3.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 487,348 shares of the biopharmaceutical company’s stock worth $134,035,000 after purchasing an additional 16,756 shares during the period. Swiss National Bank raised its position in shares of Alnylam Pharmaceuticals by 0.3% in the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after buying an additional 1,000 shares in the last quarter. Eagle Asset Management Inc. boosted its stake in Alnylam Pharmaceuticals by 25.7% during the third quarter. Eagle Asset Management Inc. now owns 309,589 shares of the biopharmaceutical company’s stock valued at $85,889,000 after buying an additional 63,385 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after buying an additional 8,462 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,986 shares of company stock valued at $20,397,849. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ALNY. Piper Sandler reaffirmed an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. HC Wainwright lifted their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Scotiabank decreased their price target on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. Needham & Company LLC restated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Finally, Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $246.75 on Friday. The company’s fifty day simple moving average is $254.32 and its two-hundred day simple moving average is $262.22. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market cap of $31.94 billion, a PE ratio of -113.71 and a beta of 0.35. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.